CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Avastin for Ovarian Cancer - Details

Project Number PC0047-000
Brand Name Avastin
Generic Name Bevacizumab
Strength 25mg/mL
Tumour Type Gynecology
Indication Ovarian Cancer
Funding Request In combination with paclitaxel and carboplatin for the front-line treatment of epithelial ovarian, fallopian tube or primary peritoneal cancer patients with high risk of relapse (stage III sub-optimally debulked, or stage III unresectable, or stage IV patients
Review Status Complete
Pre Noc Submission Yes
NOC Date N/A
Manufacturer Hoffmann-La Roche Limited
Sponsor Hoffmann-La Roche Limited
Submission Date November 28, 2014
Submission Deemed Complete December 5, 2014
Submission Type Initial
Prioritization Requested Requested and Not Granted
Stakeholder Input Deadline ‡ December 12, 2014
Check-point meeting January 26, 2015
pERC Meeting March 19, 2015
Initial Recommendation Issued April 2, 2015
Feedback Deadline ‡ April 17, 2015
pERC Reconsideration Meeting May 21, 2015
Final Recommendation Issued June 4, 2015
Notification to Implement Issued June 19, 2015
Therapeutic Area Ovarian Cancer
Recommendation Type Reimburse with clinical criteria and/or conditions

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.